Cochrane · systematic review · CD012555
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
Sutherland, A, Naessens, K, Plugge, E, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
7
No studies
7
Included studies
NR
No studies 7 · 50%Ungraded 0 · 0%Very low 2 · 14.3%Low 2 · 14.3%Moderate 3 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Olanzapine compared to placebo/no treatment for the prevention and treatment of cancer‐related nausea and vomiting in adults
Population: adults with cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No nausea or vomiting over trial period Olanzapine vs placebo/no treatment | RR 1.98 [1.59, 2.47] | NR | Moderate Downgraded: inconsistency |
Serious adverse events Olanzapine vs placebo/no treatment | RR 2.46 [0.48, 12.55] | NR | Low Downgraded: imprecision, inconsistency |
Participant preference ‐ wish to use drug in next treatment Olanzapine vs placebo/no treatment | RR 1.43 [0.97, 2.09] | NR | Moderate Downgraded: imprecision |
Quality of life Olanzapine vs placebo/no treatment | no estimate extracted | NR | No studies |
Patient Global Impression of Change Olanzapine vs placebo/no treatment | no estimate extracted | NR | No studies |
Other adverse events Olanzapine vs placebo/no treatment | RR 1.71 [0.99, 2.96] | NR | Low Downgraded: imprecision, inconsistency |
Somnolence/fatigue Olanzapine vs placebo/no treatment | RR 2.33 [1.3, 4.18] | NR | Moderate Downgraded: inconsistency |
Olanzapine compared to NK1 antagonist for the prevention and treatment of cancer‐related nausea and vomiting in adults
Population: adults with cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No nausea or vomiting over trial period Olanzapine vs NK1 antagonist | no estimate extracted | NR | No studies |
Serious adverse events Olanzapine vs NK1 antagonist | RR 0.33 [0.02, 7.32] | NR | Very low Downgraded: risk of bias, imprecision |
Participant satisfaction Olanzapine vs NK1 antagonist | no estimate extracted | NR | No studies |
Quality of life Olanzapine vs NK1 antagonist | no estimate extracted | NR | No studies |
Patient Global Impression of Change Olanzapine vs NK1 antagonist | no estimate extracted | NR | No studies |
Other adverse events Olanzapine vs NK1 antagonist | no estimate extracted | NR | No studies |
Somnolence/fatigue Olanzapine vs NK1 antagonist | RR 1.33 [0.4, 4.49] | NR | Very low Downgraded: risk of bias, imprecision |